100 Most Influential People in Global Health List Includes
Dr. Shastri, Based on Development of Proprietary Diagnostic
Tool Powering Precision Blood Tests for Early Alzheimer's Disease
Diagnosis
CARLSBAD, Calif., May 2, 2024
/PRNewswire/ -- ALZpath, Inc., a leading developer of innovative
diagnostic tools and solutions for Alzheimer's disease and related
dementias, announced today that TIME Magazine has named ALZpath's
Co-Founder and CEO, Venkat Shastri,
PhD, to the inaugural TIME100 Health list. This annual list
recognizes the impact, innovation, and achievement of 100 of the
world's most influential individuals who most impacted global
health this year.
Dr. Shastri co-founded ALZpath with Eric
Reiman, MD and Jerre Stead,
driven by a mission to transform the diagnosis, treatment and
management of Alzheimer's disease.
"I am honored to be listed among TIME100's health leaders and
applaud their dedication to enhancing healthcare outcomes around
the world," said Venkat Shastri,
PhD, Co-Founder and CEO of ALZpath. "This honor recognizes the
efforts of the entire ALZpath team to make our highly sensitive
pTau217 blood-based test a routine part of the Alzheimer's disease
diagnosis and treatment paradigm, so that patients can be diagnosed
earlier, with more accuracy, and benefit from a new generation of
therapies that are both approved and in clinical trials.
"Thank you to TIME for recognizing the tremendous work of Venkat
and the ALZpath team in developing novel diagnostic solutions that
will help transform Alzheimer's disease research and patient care,"
said Board Chair and Co-Founder Jerre
Stead. "We are dedicated to reshaping the Alzheimer's care
continuum through timely and accurate diagnosis, improving the
lives of patients and those living with risk of Alzheimer's
disease."
Working together with Andreas
Jeromin, PhD, and Jacob
Hunter, Dr. Shastri, and the ALZpath team pioneered the
development of proprietary antibodies, including one that detects
pTau217, an important biomarker for early-stage Alzheimer's disease
diagnosis, that is now being utilized in standard blood-based tests
throughout the United States.
In a recent study published by JAMA Neurology, the ALZpath
pTau217 test demonstrated levels of accuracy comparable to
traditional methods like PET imaging and cerebral spinal fluid
testing, which are expensive, invasive and unscalable. The test,
known as ALZpath Dx, is currently available as a laboratory
developed test (LDT) for clinical diagnostic use and clinical
trials. The test can also be ordered online by healthcare
providers.
The full list and related tributes appear in the May 13, 2024 issue of TIME, available on
newsstands on Friday, May 3, and now
at time.com/time100health.
About ALZpath
ALZpath is a leading developer of innovative diagnostic tools
and solutions for Alzheimer's disease and related dementias. The
novel ALZpath pTau217 antibody is transforming Alzheimer's disease
diagnosis and treatment monitoring, providing accurate and
accessible tools for researchers and healthcare professionals
worldwide.
ALZpath Dx is available throughout the
United States as a laboratory developed Test (LDT) for
clinical diagnostic use, clinical trials and other research
purposes and can be ordered online by healthcare providers. The
company is also collaborating with researchers, clinicians, and
industry partners to accelerate the discovery of new treatments and
improve patient care. To learn more about the company, please visit
https://alzpath.bio and follow us on LinkedIn.
About TIME
TIME is the 101-year-old global media brand that reaches a
combined audience of over 120 million around the world through its
iconic magazine and digital platforms. With unparalleled access to
the world's most influential people, the trust of consumers and
partners globally, and an unrivaled power to convene, TIME's
mission is to tell the essential stories of the people and ideas
that shape and improve the world. Today, TIME also includes the
Emmy Award®-winning film and television division TIME Studios; a
significantly expanded live events business built on the powerful
TIME100 and Person of the Year franchises and custom experiences;
TIME for Kids, which provides trusted news with a focus on news
literacy for kids and valuable resources for teachers and families;
the award-winning branded content studio Red Border Studios; the
website-building platform TIME Sites; the sustainability and
climate action division TIME CO2; the new e-commerce and content
platform TIME Stamped, and more.
Media Contact:
Nechama
Rosengarten
FINN Partners
nechama.rosengarten@finnpartners.com
View original
content:https://www.prnewswire.com/news-releases/time-selects-alzpath-co-founder-dr-venkat-shastri-as-inaugural-member-of-time100-health-ranking-302134407.html
SOURCE ALZpath, Inc.